A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: BIOLOGICAL: Pertuzumab (ZRC-3277)|BIOLOGICAL: Pertuzumab (Perjeta®)
Sponsor: Zydus Lifesciences Limited